Objective: The 2019 coronavirus disease (COVID-19) epidemic has raised international concern.Mental health is becoming an issue that cannot be ignored in our fight against it. This study aimed to explore the prevalence and factors linked to anxiety and depression in hospitalized patients with COVID-19. Methods:A total of 144 patients diagnosed with COVID-19 were included in this study. We assessed depression and anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS), and social support using the Perceived Social Support Scale (PSSS) among patients at admission. Multivariate linear regression analyses were performed to identify factors associated with symptoms of anxiety and depression.Results: Of the 144 participants, 34.72% and 28.47% patients with COVID-19 had symptoms of anxiety or depression, respectively. The bivariate correlations showed that less social support was correlated with more anxious (r=-0.196, p<0.05) and depressive (r=-0.360，p<0.05) symptoms All rights reserved. No reuse allowed without permission. : medRxiv preprint among patients with COVID-19. The multiple linear regression analysis showed that gender (β=1.446, p=0.034), age (β=0.074, p=0.003), oxygen saturation (β =-2.140, p=0.049), and social support (β =-1.545, p=0.017) were associated with anxiety for COVID-19 patients. Moreover, age (β=0.084, p=0.001), family infection with SARS-CoV-2 (β =1.515, p=0.027) and social support (β =-2.236, p＜0.001) were the factors associated with depression. Conclusion:Hospitalized patients with COVID-19 presented features of anxiety and depression.Mental concern and appropriate intervention are essential parts of clinical care for those who are at risk.

We develop the complex scaling method within the framework of the relativistic mean-field (RMF) model. With the self-consistent nuclear potentials from the RMF model, the complex scaling method is used to study single-particle resonant states in spherical nuclei. As examples, the energies and widths of low-lying neutron resonant states in 120 Sn are obtained. The results are compared with those from the real stabilization method, the scattering phase-shift method, and the analytic continuation in the coupling constant approach and satisfactory agreements are found.

Interferons (IFNs) are proteins produced by a variety of cells during the process of virus infection. It can activate the transcription of multiple functional genes in cells, regulate the synergistic effect of multiple signaling pathways, and mediate a variety of biological functions such as antiviral activity and immune regulation. The symptoms of hosts infected with African swine fever virus (ASFV) depend on the combined interaction between viruses and the host. However, it is unclear whether IFNs can be used as an emergency preventive treatment for ASFV. This study focused on the use of recombinant porcine IFNs, produced by Escherichia coli, to inhibit the replication of ASFV. The activity of IFN against ASFV was detected using primary alveolar macrophages at different doses through immunofluorescence assays and quantitative real-time PCR. We found that both 1000 and 100 U/mL doses significantly inhibited the replication of ASFV. Meanwhile, we found that IFNs could significantly trigger the production of a variety of IFN-induced genes (IFIT1, IFITM3, Mx-1, OASL, ISG15, PKR, GBP1, Viperin, BST2, IRF-1, and CXCL10) and MHC molecules, which play key roles in resistance to virus infection. Peripheral blood samples were also obtained from surviving pigs treated with IFNs, and the viral load was determined. Consistent with in vitro tests, low-dose (10 5 U/kg) recombinant porcine IFNs (PoIFN-α and PoIFN-γ) significantly reduced viral load compared to that with high-dose (10 6 U/kg) treatment. Our results suggest that recombinant porcine IFNs have high antiviral activity against ASFV, providing a new strategy for the prevention of African swine fever.

Highlights d Naproxen exhibits antiviral activity against both influenza A and B viruses d Naproxen antagonizes CRM1-mediated nucleoprotein nuclear export of influenza A and B viruses d Naproxen directly binds to nucleoproteins of influenza A and B viruses d Naproxen provides therapeutic protection to mice infected with influenza B virus